Artenimol
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Artenimol |
| DrugBank ID | DB11638 |
| Brand Names (EU) | Artenimol |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.87% |
Approved Indication (EMA)
Eurartesim is indicated for the treatment of uncomplicated Plasmodium falciparum malaria in adults, children and infants 6 months and over and weighing 5 kg or more. Consideration should be given to official guidance on the appropriate use of antimalarial agents.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | malaria | 99.87% | DL |
| 2 | Smouldering systemic mastocytosis | 98.67% | DL |
| 3 | lymphoadenopathic mastocytosis with eosinophilia | 98.42% | DL |
| 4 | systemic mastocytosis | 98.28% | DL |
| 5 | Plasmodium vivax malaria | 97.30% | DL |
| 6 | rheumatoid factor-positive polyarticular juvenile idiopathic arthritis | 97.17% | DL |
| 7 | juvenile chronic polyarthritis | 96.61% | DL |
| 8 | rheumatoid nodulosis | 96.57% | DL |
| 9 | juvenile idiopathic arthritis | 96.57% | DL |
| 10 | West syndrome | 96.33% | DL |
| 11 | intellectual disability, X-linked, with or without seizures, arx-related | 95.87% | DL |
| 12 | echinococcus granulosus infectious disease | 94.27% | DL |
| 13 | alveolar echinococcosis | 93.21% | DL |
| 14 | gastrin secretion abnormality | 93.02% | DL |
| 15 | cystic echinococcosis | 93.00% | DL |
| 16 | enterobiasis | 92.44% | DL |
| 17 | pseudoachondroplasia | 92.11% | DL |
| 18 | juvenile arthritis due to defect in LACC1 | 91.98% | DL |
| 19 | acne (disease) | 90.97% | DL |
| 20 | monosomy X | 90.56% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.